The tumour suppressor role of PAX6 in NSCLC, which we propose in this paper, is in line with a number of methylation studies, which indicated that PAX6 promoter methylation is common in several cancers18 -21, including NSCLC15–17, and is associated with disease recurrence18 and poor survival17,19. This evidence concerns the gene PAX6 and neoplasm.